Last updated: February 7, 2026
Case Overview
Vanda Pharmaceuticals Inc. filed suit against Teva Pharmaceuticals USA, Inc. in the District of Columbia District Court in 2019, alleging patent infringement related to Vanda’s U.S. Patent No. 9,308,248. The patent covers a specific formulation of the drug Hetlioz, used in the treatment of circadian rhythm sleep disorders. The dispute centered around Teva’s filing for abbreviated new drug applications (ANDA), seeking approval to market a generic version of Hetlioz prior to patent expiration.
Patent Details
- Patent Number: 9,308,248
- Filing Date: March 22, 2016
- Issued: April 5, 2016
- Claimed Invention: A controlled-release formulation of tasimelteon (the active ingredient in Hetlioz), with specific characterizations related to its efficacy and release profile.
Core Allegations
Vanda argued Teva's ANDA products infringed upon the '248 patent by proposing a generic formulation with a similar release profile. The complaint claimed that Teva's formulation did not deviate sufficiently from Vanda’s proprietary formulation to avoid infringement, asserting both literal infringement and infringement under the doctrine of equivalents.
Litigation Timeline and Key Developments
-
Initial Complaint (October 2019): Vanda filed for patent infringement, seeking injunctive relief and damages.
-
Teva’s Response and ANDA Filing: Teva responded with a paragraph IV certification, claiming the patent was invalid, unenforceable, and not infringed.
-
Claim Construction and Waiver Proceedings (2020): The court held hearings on claim construction, adopting Vanda's proposed interpretation of key claims related to the formulation’s specific release characteristics.
-
Summary Judgment Motions (2021): Both parties filed motions. Vanda sought a ruling that Teva’s product infringed and that the patent was valid; Teva challenged patent validity and argued non-infringement.
-
Trial and Jury Proceedings (2022): The case proceeded to trial, with the jury finding that Teva's generic did infringe the '248 patent and that the patent was valid.
-
Post-Trial & Injunction: The court issued an injunction preventing Teva from marketing the generic until the patent's expiration, which was set for 2030.
Key Legal Issues
- Infringement Scope: Whether Teva’s formulation infringed on the patent claims, especially under the doctrine of equivalents.
- Patent Validity: Whether the patent claims were patent-eligible, novel, and non-obvious in light of prior art.
- Infringement Damages: Calculation of damages for the period following infringement, accounting for lost sales.
Outcome & Significance
The court found in favor of Vanda on both infringement and validity, reaffirming the patent’s scope. The preliminary injunction remains in force until 2030, effectively barring Teva from marketing its generic formulation. The case underscores the strength of formulation patents in the pharmaceutical industry and highlights the challenges faced by generic manufacturers attempting to design around such patents.
Strategic Insights
- Patent Doctrine of Equivalents: Courts are increasingly scrutinizing claims closely, especially for formulation patents. Claim language interpretations are critical.
- Patent Validity Challenges: Despite potential prior art, patents with detailed formulation claims can withstand validity challenges if specific attributes are demonstrated to be non-obvious.
- Market Impact: The decision preserves Vanda’s market exclusivity for Hetlioz for an extended period, generating significant revenue and deterring generic entry.
Key Takeaways
- Patent strength in formulation-specific drugs remains vital for pharmaceutical exclusivity.
- Paragraph IV certifications prompt litigation, often culminating in patent affirmances rather than invalidation.
- Courts are willing to uphold patent claims closely tied to specific formulation parameters.
- Infringement cases may extend over multiple years, reflecting complex claim construction and validity analyses.
- Patent infringement suits serve as strategic tools for brand-name drug companies to delay generics’ market entry.
FAQs
1. What is the significance of a paragraph IV certification?
A paragraph IV certification indicates the generic applicant's belief that the patent is invalid, unenforceable, or not infringed. It triggers patent litigation and delays approval of the generic drug.
2. How does claim construction influence infringement analysis?
The court’s interpretation of patent claims determines the scope of protection. Narrow interpretations can limit infringement, while broader interpretations may increase infringement risk.
3. Can a patent be invalidated during infringement litigation?
Yes, defendants often argue invalidity defenses based on prior art, obviousness, or insufficient novelty, which courts evaluate before deciding infringement.
4. What remedies result from patent infringement in pharma cases?
Injunctions prevent ongoing or future infringement; damages compensate for past infringement, often based on lost sales or reasonable royalty calculations.
5. How long can patent disputes last in pharma litigation?
Litigation can span several years—typically 2 to 5 years—depending on claim construction, discovery, and trial complexity.
Sources:
[1] District Court Opinion, Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-02202.
[2] U.S. Patent No. 9,308,248.
[3] FDA Abbreviated New Drug Application (ANDA) process guidelines.
